TY - JOUR A1 - Godard, A. A1 - Kalot, G. A1 - Privat, M. A1 - Bendellaa, M. A1 - Busser, B. A1 - Wegner, Karl David A1 - Denat, F. A1 - Le Guevel, X. A1 - Coll, J.-L. A1 - Paul, C. A1 - Bodio, E. A1 - Goze, C. A1 - Sancey, L. T1 - NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer N2 - Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting. KW - NIR-II KW - Fluorescent dye KW - In vivo imaging KW - Ovarian cancer KW - Antibody conjuagtes KW - Bioimaging PY - 2023 U6 - https://doi.org/10.1021/acs.jmedchem.3c00100 SN - 0022-2623 VL - 66 IS - 7 SP - 5185 EP - 5195 PB - ACS Publications AN - OPUS4-57293 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -